136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial
Journal
Journal of Thoracic Oncology
Journal Volume
11
Journal Issue
4
Date Issued
2016
Author(s)
SDGs
Other Subjects
corticosteroid; durvalumab; osimertinib; anemia; Article; cancer combination chemotherapy; clinical article; controlled clinical trial; controlled study; corticosteroid therapy; diarrhea; drug dose escalation; drug efficacy; drug safety; drug tolerability; EGFR gene; gene mutation; human; monotherapy; nausea; non small cell lung cancer; phase 1 clinical trial (topic); priority journal; receptor gene; vomiting
Publisher
Elsevier Inc
Type
journal article